M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
Clara Sattler de Sousa e Brito to lead discovery solutions from Q3 2026, while Robert Machinek takes over as Head of Strategy & Business Development
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
At the center of the collapse is opposition from the Federal Trade Commission
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
He has been associated with the Zydus Group since 2009
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
